Epigenetic Regulation of Cancer in Response to Chemotherapy
- 1st Edition, Volume 158 - March 27, 2023
- Imprint: Academic Press
- Editors: Joseph Landry, Swadesh Das, Paul B. Fisher
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 4 1 8 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 4 1 9 - 1
Epigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume prese… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteEpigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting chapters on timely topics, including Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in Cancer, A Role for the Epigenome in Cancer Cell Drug Tolerance, Histone Methylation and X Chromosomal Genes in Metastasis of Breast Cancer, Targeting Epigenetic Regulation Using Small Molecule Inhibitors, Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung Cancer, From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia), and more.
Additional chapters cover Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning, and Knowledge-Based Methods, Probing on the Mechanisms of lncRNAs on Cancer Drug Resistance, Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic Perspectives, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Cancer Research series
- Includes the latest information on the Epigenetic Regulation of Cancer in Response to Chemotherapy
Researchers and students
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: The epigenome and the many facets of cancer drug tolerance
- Abstract
- 1: Principles of non-genetic drug tolerance
- 2: The hallmarks of cancer drug tolerance
- 3: Epigenetics in drug tolerance
- References
- Chapter Two: Epigenetically programmed resistance to chemo- and immuno-therapies
- Abstract
- 1: Epigenetic dysregulation in cancer and therapeutic resistance
- 2: Chemoresistance
- 3: Epigenetic modifications drive cancer progression and chemoresistance
- 4: Epigenetic modifications drive resistance to immunotherapies
- 5: Targeting epigenetic modifications to overcome chemoresistance and immune evasion
- 6: Conclusions
- Competing interests
- References
- Chapter Three: Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
- Abstract
- 1: Introduction
- 2: DNA methylation
- 3: Histone modifications
- 4: Combination epigenetic therapy
- 5: Conclusions
- References
- Further reading
- Chapter Four: Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer
- Abstract
- 1: Lung cancer statistics
- 2: Overview of major types of lung cancer
- 3: Conventional and other lung cancer therapies and their significant limitations
- 4: Surgery and radiation therapy for lung cancer
- 5: Histone deacetylases (HDACs) in lung cancer pathogenesis
- 6: Current scenario and chemistry of HDAC inhibitors
- 7: HDAC inhibitor-based monotherapy toward lung cancer
- 8: HDACi together with other chemotherapeutics against lung cancer
- 9: Clinical studies of HDACi with immune checkpoint inhibitors toward lung cancer
- 10: Conclusion and future suggestions
- Acknowledgments
- References
- Chapter Five: From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia)
- Abstract
- 1: Introduction
- 2: Dormancy, diapause, and quiescence
- 3: Artemia used as an animal model to study cancer dormancy
- 4: Epigenetic regulation of chromatin structure as the central mechanism to the cellular quiescence transition
- 5: Broader factors and signaling pathways conserved between Artemia, mouse, and human cancers
- 6: Conclusion and future perspectives
- Acknowledgment
- References
- Chapter Six: Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines
- Abstract
- 1: Introduction
- 2: Datasets and methods used to develop predictive multi-marker linear regression models
- 3: Developing the predictive models
- 4: Discussion of linear progression models and applications for gene identification and predictors of taxane therapeutic response
- 5: Future perspectives
- Acknowledgments
- References
- Chapter Seven: Epigenetic adaptations in drug-tolerant tumor cells
- Abstract
- 1: Introduction
- 2: Epigenetic regulations
- 3: Drug tolerant tumor cells (DTPs) and their adaptations
- 4: Epigenetics and associated changes—Key to DTP emergence and survival
- 5: Conclusion and future perspectives
- References
- Chapter Eight: The epigenetic regulation of cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence
- Abstract
- 1: Introduction
- 2: A short primer on epigenetics
- 3: The limited success of epigenetic-targeted therapies treating solid tumors
- 4: A proposed novel use for epigenetic-targeted therapies
- 5: States which promote cancer cell recovery from therapy exposure
- 6: Strategies to prevent recovery from therapy exposure
- 7: Future directions
- Acknowledgments
- References
- Chapter Nine: Targeting the super elongation complex for oncogenic transcription driven tumor malignancies: Progress in structure, mechanisms and small molecular inhibitor discovery
- Abstract
- 1: Introduction of SEC structure and function
- 2: Relationship between SEC and transcriptional regulation
- 3: SEC dysregulation and cancer
- 4: Inhibitors targeting SEC or regulating SEC components
- 5: Future perspective
- References
- Edition: 1
- Volume: 158
- Published: March 27, 2023
- No. of pages (Hardback): 438
- No. of pages (eBook): 438
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443194184
- eBook ISBN: 9780443194191
JL
Joseph Landry
Joseph Landry works at Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Affiliations and expertise
Institute of Molecular Medicine, Virginia Commonwealth University, VA, USASD
Swadesh Das
Dr. Swadesh Das works at Massey Cancer Center, Richmond, Virginia, USA.
Affiliations and expertise
Massey Cancer Center, Richmond, VA, USAPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USARead Epigenetic Regulation of Cancer in Response to Chemotherapy on ScienceDirect